Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients
Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
Leukemia Recent News
AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment
Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial
AbbVie's Ibrutinib/Venetoclax Combo Potentially Chemo-free, Fixed-Duration Treatment Option in Leukemia
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing Estimates
Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial
Roche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive Opinion
Verastem Shares Hit Highest Level Since 2015 On Duvelisib Data
Exclusive: Moleculin CEO Says Acute Myeloid Leukemia Candidate Could Be 'Remarkable'
TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track
StreetSweeper Short Bio-Path: 'Unfortunate' Analyst Support, Little Executive Biotech Experience
Lumber Liquidators CEO Diagnosed With 'Very Treatable' Form Of Leukemia
What Sets Juno Therapeutics Inc Apart In Immunotherapy Space?
IBM's Watson Coming to Smartphones Soon (IBM)